Key statistics dashboard for Adial Pharmaceuticals, Inc. (ADIL). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder.
Stock Data
| Price | $5.24 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.30 |
| Price / Book | 148.13 |
| P/S | 0.00 |
| P/FCF | -0.43 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 5.63 |
| Quick Ratio | 5.63 |
| Cash Ratio | 5.61 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -20.02 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.03 |
| Cash per share | 6.21 |
| FCF per share | -2.41 |
| Tangible Book Value per share | 0.03 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 1.00 |
Related companies: ACXP · APRE · BCDA · BCLI · CDIO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of ADIL: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks